White Knight Strategic Wealth Advisors LLC purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 14,391 shares of the company’s stock, valued at approximately $732,000.
Several other hedge funds have also recently modified their holdings of NVO. Godfrey Financial Associates Inc. purchased a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $25,000. WealthCollab LLC raised its holdings in shares of Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after buying an additional 260 shares during the last quarter. American National Bank & Trust purchased a new position in shares of Novo Nordisk A/S in the fourth quarter worth $28,000. Maseco LLP acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $29,000. Finally, Jackson Grant Investment Advisers Inc. acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $29,000. Institutional investors and hedge funds own 11.54% of the company’s stock.
Wall Street Analyst Weigh In
NVO has been the topic of several research reports. Deutsche Bank Aktiengesellschaft downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target for the company in a research report on Tuesday, March 3rd. Sanford C. Bernstein initiated coverage on Novo Nordisk A/S in a research note on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price target on the stock. Wall Street Zen raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $65.56.
Novo Nordisk A/S News Roundup
Here are the key news stories impacting Novo Nordisk A/S this week:
- Positive Sentiment: Wegovy’s oral tablet is gaining traction in the U.K. and could provide Novo Nordisk with an early European launch path, which may help support future growth as it expands beyond injections. Article Title
- Positive Sentiment: Bank of America data indicates oral Wegovy is already accounting for roughly one-third of all Wegovy prescriptions, suggesting strong adoption and continued momentum in Novo Nordisk’s weight-loss franchise. Article Title
- Neutral Sentiment: Brokerages continue to rate Novo Nordisk as a “Hold,” reinforcing a wait-and-see view as the company balances growth opportunities against mounting operational and competitive pressures. Article Title
- Negative Sentiment: Novo Nordisk confirmed a security incident involving stolen clinical trial data after hackers reportedly demanded a $25 million ransom and began leaking information, raising concerns about data security, regulatory exposure, and reputational damage. Article Title
Novo Nordisk A/S Stock Down 0.7%
NYSE:NVO opened at $43.20 on Friday. The firm has a market capitalization of $192.89 billion, a P/E ratio of 10.14, a PEG ratio of 3.89 and a beta of 0.78. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $74.38. The company’s fifty day moving average price is $42.81 and its 200-day moving average price is $45.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56.
Novo Nordisk A/S (NYSE:NVO – Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The firm had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.45 EPS for the current year.
About Novo Nordisk A/S
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.
The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.
Featured Articles
- Five stocks we like better than Novo Nordisk A/S
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
